title: [A therapeutic improvement: second generation tyrosine kinase inhibitors (TKI 2) in the treatment of chronic myelogenous leukemia].
abstract: Second-generation tyrosine kinase inhibitors (TKI 2) represent a recent important improvement in the treatment of Philadelphia positive leukemias. These agents are a suitable major option if resistance or significant imatinib intolerance occurs in chronic and accelerated phase CML. They are now introduced as first line therapy in chronic phase CML where they induce cytogenetic and molecular response rates never seen to date, which is promising for long-term survival. We propose here an analysis of the main current data available for the use of TKI 2 in CML.
authors.affiliation: Hôpital Édouard-Herriot, hématologie clinique, Lyon Cedex, France.
authors.forename: Marine
authors.initials: M
authors.lastname: Demarquet
authors.forename: Hélène
authors.initials: H
authors.lastname: Labussière-Wallet
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Nicolas-Virelizier
authors.forename: Franck-Emmanuel
authors.initials: FE
authors.lastname: Nicolini
mesh_terms: D000814:Aniline Compounds / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001752:Blast Crisis / Q000188:drug therapy*; D000069439:Dasatinib; D006801:Humans; D015465:Leukemia, Myeloid, Accelerated Phase / Q000188:drug therapy*; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy*; D009570:Nitriles / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use
chemical_list: D000814:Aniline Compounds; D000970:Antineoplastic Agents; D009570:Nitriles; D011743:Pyrimidines; D011804:Quinolines; D013844:Thiazoles; C471992:bosutinib; D011505:Protein-Tyrosine Kinases; C498826:nilotinib; D000069439:Dasatinib